BIIB Q4 2022 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q4 2022 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.5B-6.9% YoY

Gross Profit

$2.0B77.6% margin

Operating Income

$558M21.9% margin

Net Income

$550M21.6% margin

EPS (Diluted)

$3.79

QoQ Revenue Growth

+1.4%

Cash Flow

Operating Cash Flow

-$175M

Free Cash Flow

-$262M

Stock-Based Comp.

$67M

Balance Sheet

Total Assets

$24.6B

Total Liabilities

$11.2B

Stockholders' Equity

$13.4B

Cash & Equivalents

$3.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.7B	-6.9%
Gross Profit	$2.0B	$2.1B	-4.9%
Operating Income	$558M	$507M	+10.1%
Net Income	$550M	$368M	+49.5%

Revenue Segments

MS Product Revenues

$1.3B43%

TYSABRI product

$488M16%

SPINRAZA

$459M15%

Fumarate

$448M15%

Interferon

$310M10%

Geographic Segments

Non-US

$1.1B55%

UNITED STATES

$850M45%